Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
Isa Neshandar Asli1, Nariman Mosaffa, Mehdi Mogharrabi
1Department of Nuclear Medicine, Taleghani Hospital.
Objective:
We evaluated the potential detrimental cytogenetic effects of Tc-methoxyisobutyl isonitrile (MIBI) and I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, respectively.
Methods:
Mononuclear leukocytes were isolated both before and after radiopharmaceutical administration and subsequently cultured. Micronuclei frequency was then assessed and microscopic evaluation of apoptosis was conducted.
Results:
Small statistically insignificant augmentation in the percentage of micronuclei from 10.9+/-3.8 to 11.3+/-2.4% was observed in the Tc-MIBI group. In contrast, I elicited a notable augmentation of micronuclei from 6.3+/-2.2 to 9.6+/-3.1 at 3.7 GBq, and 6+/-1.5 to 9.2+/-2.7 at 5.55 GBq (P<0.05).
Conclusion:
Our results showed that there were no remarkable alterations either in the micronuclei incidence or in the percentage of apoptotic lymphocytes after in-vivo exposure to radiopharmaceutical imaging, which provides evidence to reduce the growing concern about the safety issue of cardiac imaging with Tc-MIBI, whereas the deleterious effects of I must be considered when it is applied to thyroid cancer treatment.
